Table 2.
Case Series Summary of Bleeding Events.
| Patient Number | OAC at Time of Bleed | Cumulative Duration of OAC | DOAC Dosed Appropriately? | HAS-BLED Score | Concurrent Antiplatelet Medication | Warfarin % Values in Subtherapeutic Range (SubR%), Therapeutic Range (TR%), Supratherapeutic Range (SupraR%) | Major Bleed: Type of Bleed, INR (If Documented), Other Comments |
CRNMB/Minor Bleed: Type of Bleed, INR (If Documented), Other Comments |
||
|---|---|---|---|---|---|---|---|---|---|---|
| SubR% | TR% | SupraR% | ||||||||
| 1 | Warfarin | 6 mos | - | 4 | ASA 81 mg | 40 | 20 | 40 | GI bleed, INR 1.2 | - |
| 2 | Warfarin | 13 mos | - | 4 | None | 23 | 46 | 31 | - | GI bleed ×2 |
| 3 | Warfarin | 54 mos | - | 3 | None | 41 | 37 | 22 | - | GI bleed |
| 3 | Warfarin | 12 mos | - | 2 | None | 10 | 63 | 27 | - | GI bleed |
| 5 | Warfarin | 44 mos | - | 4 | None | 68 | 27 | 5 | - | Epistaxis ×2 |
| 6 | Warfarin | 21 mos | - | 3 | None | 32 | 32 | 36 | Hematoma arm requiring surgical intervention (Transfuse 2U PRBC), INR 5.6 | Epistaxis ×4 |
| 7 | Warfarin | 20 mos | - | 3 | None | 18 | 40 | 42 | Hematoma leg—(Transfuse 4U PRBC, Reduction Hgb ≥ 2 g/dL) GI bleed—(Transfuse 4U PRBC, Reduction Hgb ≥ 2 g/dL) Hemoptysis—(Transfuse 2U PRBC) |
- |
| 8 | Warfarin | 49 mos | - | 6 | ASA 81 mg | 35 | 42 | 23 | - | Hemoptysis |
| 9 | Warfarin | 7 mos | - | 4 | None | 31 | 26 | 43 | Urologic bleed—(Transfuse 2U PRBC, Reduction Hgb ≥ 2 g/dL) | - |
| 10 | Warfarin | 5 mos | - | 2 | ASA 81 mg | 6 | 50 | 44 | - | HD access site ×2 |
| 11 | Warfarin | 48 mos | - | 4 | ASA 81 mg | 40 | 60 | 0 | - | Epistaxis |
| 12 | Warfarin | 43 mos | - | 4 | ASA 81 mg, Clopidogrel 75 mg | 50 | 50 | 0 | - | HD access site, Urologic |
| 13 | Warfarin | 8 mos | - | 3 | ASA 81 mg | 58 | 16 | 26 | - | Hemoptysis, INR 7.8 |
| 14 | Warfarin | 73 mos | - | 3 | None | 32 | 47 | 21 | GI bleed—(Transfuse 3U PRBC) | - |
| 15 | Warfarin | 9 mos | - | 2 | None | 22 | 57 | 21 | GI bleed—(Transfuse 2U PRBC), INR > 8.8 | HD access site, Hematoma |
| 16 | Warfarin | 4 mos | - | 4 | ASA 325 mg | 29 | 57 | 14 | GI bleed—(Transfuse 2U PRBC, Reduction Hgb ≥ 2 g/dL), INR 7.1 | - |
| 17 | Warfarin | 10 mos | - | 5 | ASA 81 mg | 2 | 50 | 48 | - | Epistaxis |
| 18 | Warfarin | 8 mos | - | 3 | None | 13 | 54 | 33 | GI bleed—(Transfuse 2U PRBC, Reduction Hgb ≥ 2 g/dL) | - |
| 19 | Warfarin | 1 month | - | 5 | ASA 81 mg | 36 | 24 | 40 | - | HD access site |
| Dabigatran 150 BID | 1 month | No, avoid use | See above | ASA 81 mg | - | - | - | - | GI bleed, Bruising | |
| Warfarin | 5 mos | - | See above | ASA 81 mg | See above | See above | See above | GI bleed, Death/Sepsis | - | |
| 20 | Warfarin | 52 mos | - | 3 | None | 77 | 10 | 13 | - | - |
| Dabigatran 75 BID | 1 month | No, avoid use | See above | None | - | - | - | GI bleed-(Transfuse 2U PRBC, Reduction Hgb ≥ 2 g/dL) | - | |
| 21 | Warfarin | 1 month | - | 4 | ASA 81 mg | 0 | 33 | 67 | GI bleed-(Transfuse 4U PRBC, Reduction Hgb ≥ 2 g/dL) | - |
| Apixaban 2.5 BID | 2 mos | No, dose reduced | See above | ASA 81 mg | - | - | - | - | - | |
| 22 | Warfarin | 47 mos | - | 3 | ASA 81 mg | 37 | 58 | 5 | - | HD access site ×2 |
| Apixaban 2.5 BID | 14 mos | No, dose reduced | See above | None | - | - | - | - | - | |
| 23 | Warfarin | 2 mos | - | 5 | ASA 81 mg | 67 | 33 | 0 | - | - |
| Apixaban 2.5 BID | 1 month | No, dose reduced | See above | ASA 81 mg | - | - | - | GI bleed (Reduction Hgb ≥ 2 g/dL) | - | |
| 24 | Dabigatran 150 BID | 7 days | No, avoid use | 5 | ASA 81 mg | - | - | - | - | GI bleed |
| Apixaban 5 BID | 15 days | Yes | See above | ASA 81 mg | - | - | - | GI bleed (Transfuse 2U PRBC, Reduction Hgb ≥ 2 g/dL) | - | |
| Apixaban 2.5 BID | 24 mos | No, dose reduced | See above | None | - | - | - | - | - | |
| 25 | Apixaban 2.5 BID | 9 mos | Yes | 4 | ASA 81 mg | - | - | - | - | HD access site |
| 26 | Apixaban 2.5 BID | 2 mos | Yes | 2 | None | - | - | - | - | GI bleed |